Señales en vivo de NLTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 dic 2023 @ 16:00):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology...

Stats
Volumen de hoy	109 095
Volumen promedio	5 520.00
Capitalización de mercado	8.20M
EPS	$0 ( 2024-03-19 )
Próxima fecha de ganancias	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.284
ATR14	$0.878 (25.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Woods Robert Keith	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Palekar Rohan	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Noonberg Sarah B.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Freedland Cory S.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Baffi Robert	Buy	15 400	Stock Option (Right to Buy)

INSIDER POWER
75.01
Last 94 transactions
Buy: 7 989 742 \| Sell: 1 025 638

Volumen Correlación

Largo: -0.32 (neutral)

Corto: -0.52 (weak negative)

Signal:(16.09) Neutral

Neoleukin Therapeutics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neoleukin Therapeutics Correlación - Moneda/Commodity

-0.31
( neutral )

-0.32
( neutral )

0.32
( neutral )

-0.24
( neutral )

0.17
( neutral )

0.18
( neutral )

Neoleukin Therapeutics Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.010

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.010

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.100

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.